Peter Olson
YOU?
Author Swipe
View article: Comment on "Did the terrestrial planets of the Solar System form by pebble accretion?"
Comment on "Did the terrestrial planets of the Solar System form by pebble accretion?" Open
Morbidelli, Kleine & Nimmo (2024) (MKN) recently published a critical analysis on whether the terrestrial planets in the Solar System formed by rapid pebble accretion or by the classical route of multiple giant impacts between planetary em…
View article: Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer Open
KRASG12C inhibitors (adagrasib and sotorasib) have shown clinical promise in targeting KRASG12C-mutated lung cancers; however, most patients eventually develop resistance. In lung patients with adenocarcinoma with KRASG12C and STK11/LKB1 c…
View article: Adeno-to-squamous transition drives resistance to KRAS inhibition in<i>LKB1</i>mutant lung cancer
Adeno-to-squamous transition drives resistance to KRAS inhibition in<i>LKB1</i>mutant lung cancer Open
Summary KRAS G12C inhibitors including adagrasib and sortorasib have shown clinical promise in targeting KRAS G12C -mutated lung cancers, however, most patients eventually develop drug resistance. In lung adenocarcinoma patients with co-oc…
View article: JAMA Cardiology
JAMA Cardiology Open
science, and evidence-based health policy.Health equity, especially when supported by original science, is a leading editorial priority.
View article: JAMA Cardiology
JAMA Cardiology Open
science, and evidence-based health policy.Health equity, especially when supported by original science, is a leading editorial priority.
View article: Table S1_3to6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Table S1_3to6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC Open
Table S1, S3, S4, S5, S6
View article: Supplementary figure legends from Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3
Supplementary figure legends from Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3 Open
Supplementary figure legends
View article: Table S7 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Table S7 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC Open
Table S7
View article: Supplementary Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Supplementary Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Open
Supplementary Composite Figure File
View article: Table S1_3to6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Table S1_3to6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC Open
Table S1, S3, S4, S5, S6
View article: Supplementary Methods, Figure Legends from Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Supplementary Methods, Figure Legends from Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer Open
Supplementary Methods and Figure Legends
View article: Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy Open
KRASG12C inhibitors, including MRTX849, are promising treatment options for KRAS-mutant non–small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; however, strategies to enhance checkpoint inhibitor therapy (CIT) are needed…
View article: Table S7 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Table S7 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC Open
Table S7
View article: Figure S1-S5 from Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3
Figure S1-S5 from Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3 Open
Figure S1. PF-03084014 selective inhibits high Notch1 expression HCC cells and does not suppress normal hepatocytes proliferation; Figure S2. Intermittent dosing of PF-03084014 reduced gastrointestinal toxicity; Figure S3. Antitumor effect…
View article: Supplementary Material from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
Supplementary Material from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy Open
Supplementary Material
View article: Supplementary Figures S1 - S6 from Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Supplementary Figures S1 - S6 from Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer Open
Supplementary Figure S1. B cells in human PDAC. Supplementary Figure S2. B cells and FcRgamma-positive cells regulate murine PDAC. Supplementary Figure S3. Leukocytes and BTK in human and murine PDAC. Supplementary Figure S4. Macrophage PI…
View article: Supplementary Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Supplementary Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Open
Supplementary Table S8
View article: Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy Open
KRASG12C inhibitors, including MRTX849, are promising treatment options for KRAS-mutant non–small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; however, strategies to enhance checkpoint inhibitor therapy (CIT) are needed…
View article: Supplementary Tables from Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3
Supplementary Tables from Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3 Open
Table S1: Primer sequences; Table S2. The association of clinicopathological parameters or Notch1 expression with HCC overall survival and disease-free survival using univariate and multivariate analysis
View article: Figure S1-6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Figure S1-6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC Open
Figure S1-6
View article: Supplementary Material from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
Supplementary Material from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy Open
Supplementary Material
View article: Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Open
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cy…
View article: Figures S1-S7 from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
Figures S1-S7 from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy Open
Figures S1-S7
View article: Supplementary figure legends from Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3
Supplementary figure legends from Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3 Open
Supplementary figure legends
View article: Data from Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Data from Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer Open
Pancreas ductal adenocarcinoma (PDAC) has one of the worst 5-year survival rates of all solid tumors, and thus new treatment strategies are urgently needed. Here, we report that targeting Bruton tyrosine kinase (BTK), a key B-cell and macr…
View article: Figure S1-6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Figure S1-6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC Open
Figure S1-6
View article: Data from Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Data from Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer Open
Pancreas ductal adenocarcinoma (PDAC) has one of the worst 5-year survival rates of all solid tumors, and thus new treatment strategies are urgently needed. Here, we report that targeting Bruton tyrosine kinase (BTK), a key B-cell and macr…
View article: Supplementary Methods, Figure Legends from Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Supplementary Methods, Figure Legends from Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer Open
Supplementary Methods and Figure Legends
View article: Supplementary Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Supplementary Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Open
Supplementary Composite Figure File